Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience

BACKGROUND: A fixed 8-cycle oxaliplatin and capecitabine (XELOX) regimen has been the standard adjuvant therapy for patients with stage III colon cancer. However, completing the full-cycle of oxaliplatin is often associated with severe neurotoxicity. To spare patients from the toxic effects, without...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Jianhong, Li, Weihao, Zhang, Rongxin, Lin, Junzhong, Tang, Jinghua, Wen, Yongshan, Lu, Zhenhai, Wu, Xiaojun, Pan, Zhizhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796386/
https://www.ncbi.nlm.nih.gov/pubmed/31619288
http://dx.doi.org/10.1186/s40880-019-0400-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796386/
https://www.ncbi.nlm.nih.gov/pubmed/31619288
http://dx.doi.org/10.1186/s40880-019-0400-x

Ejemplares similares